The Hereditary Testing Market was valued at USD 7.73 billion in 2024 and is projected to reach USD 8.36 billion in 2025 and USD 17.13 billion by 2034, growing at a CAGR of 8.3% during the forecast period 2025–2034, according to Polaris Market Research. Hereditary testing, also known as genetic testing, identifies mutations in genes, chromosomes, or proteins associated with inherited disorders, enabling early disease detection and risk assessment. Increased regulatory support for genetic testing is a key factor fueling expansion. Key drivers include the increasing prevalence of genetic disorders, rising awareness of early disease detection, and advancements in next-generation sequencing technologies. North America was the largest regional market in 2024.

Next-Generation Sequencing Advances Reshape Test Economics

Rapid advances in genetic testing technologies are driving market growth. Innovations such as next-generation sequencing have enhanced the accuracy, speed, and cost-effectiveness of genetic analyses, making hereditary testing more accessible.

These improvements have facilitated the detection of a broader range of genetic mutations, and the integration of next-generation sequencing has enabled comprehensive screening for various genetic disorders. Polaris identifies faster, cost-effective, high-throughput analysis as a key market trend.

Molecular Testing Dominates the Technology Landscape

By technology, the Hereditary Testing Market is segmented into cytogenetic, biochemical, and molecular testing. Molecular testing was the dominant segment in 2024, attributed to the widespread adoption of techniques such as next-generation sequencing and polymerase chain reaction, which offer high accuracy and efficiency in detecting genetic mutations.

The integration of artificial intelligence and machine learning algorithms into molecular testing platforms has further enhanced data interpretation and variant classification.

Browse insights:

https://www.polarismarketresearch.com/industry-analysis/hereditary-testing-market

AI-Driven Genetic Analysis Opens New Opportunities

The rising integration of artificial intelligence is expected to provide several market opportunities. AI-driven genetic analysis accelerates genomic data analysis and identifies hereditary risk factors with greater accuracy and efficiency. Machine learning models detect rare genetic variants that conventional testing methods may overlook.

AI-powered platforms enable personalized risk assessments that guide targeted prevention and treatment strategies, and continuous learning improves the reliability and scope of testing over time. Increased investment in AI-driven genetic analysis enhances test accuracy and efficiency.

Direct-to-Consumer Testing and Personalized Medicine Broaden Demand

The growing adoption of direct-to-consumer genetic testing is a notable trend, with rising consumer awareness and accessibility of at-home tests driving expansion. Companies are expanding direct-to-consumer genetic testing with user-friendly digital platforms to improve accessibility and market reach.

Growing recognition of personalized medicine, which tailors healthcare to individual genetic profiles, has increased acceptance and demand as individuals and providers seek to understand genetic predispositions. The ability to identify genetic risks allows proactive health management and personalized treatment plans, reflecting a shift toward individualized healthcare. In the United States, the Genetic Information Nondiscrimination Act prohibits discrimination based on genetic information in health insurance and employment, encouraging individuals to pursue testing. Supportive regulations, funding for genetic research, and public health campaigns have also increased the availability and acceptance of genetic testing services. Ethical and privacy concerns, however, may present market challenges, according to Polaris.

Competitive Landscape and Key Players

Key players hereditary testing include CENTOGENE N.V., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, MedGenome Inc., Myriad Genetics, Inc., Natera, Inc., Quest Diagnostics Incorporated, SOPHiA GENETICS SA, Thermo Fisher Scientific Inc., Twist Bioscience Corporation, and WuXi NextCODE Genomics, Inc. Agilent Technologies, Inc. and CooperSurgical, Inc. also feature among the profiled participants.

In October 2024, Myriad Genetics, Inc. announced a collaboration with Flatiron Health, allowing physicians to order the MyRisk Hereditary Cancer Test and access results within the OncoEMR platform. Polaris rates rivalry among existing firms as high and the threat of new entrants as low.

Companies focus on expanding service offerings through research collaborations, strategic partnerships, and acquisitions, while regulatory approvals and reimbursement policies play a crucial role in market penetration. Geographic expansion, particularly in emerging markets, is a key strategy to reach a broader customer base.

More Trending Latest Reports By Polaris Market Research:

customer-success-management-market

non-invasive-cancer-diagnostics-market

military-simulation-and-virtual-training-market

laundry-chemicals-market

viral-vector-and-plasmid-dna-manufacturing-market

distributed-energy-resource-management-system-market

fetal-bovine-serum-market

rare-earth-metals-market

future-of-robotics-market

cloud-based-contact-center-market